Chardan Capital Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $8

Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference

Tvardi Therapeutics, a clinical-stage biopharmaceutical company developing STAT3-targeting therapies, announced it will present at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is advancing TTI-109 for gastrointestinal diseases and TTI-101 in a Phase 1b/2 trial for hepatocellular carcinoma, with preclinical data supporting potential in ulcerative colitis treatment.

Tvardi Therapeutics shares are trading lower. The company announced the publication of preclinical ulcerative colitis data supporting its STAT3 inhibitor program.

Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular Sciences

In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated